Qube Research & Technologies LTD Pyxis Oncology, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 68,012 shares of PYXS stock, worth $250,284. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,012
Previous 153,006
55.55%
Holding current value
$250,284
Previous $651,000
65.44%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PYXS
# of Institutions
86Shares Held
28.5MCall Options Held
134KPut Options Held
5K-
Deep Track Capital, LP Greenwich, CT4.18MShares$15.4 Million0.45% of portfolio
-
Laurion Capital Management LP New York, NY3.86MShares$14.2 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$10.3 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.56MShares$9.43 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$7.58 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $129M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...